Clinical trial
A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With "No Evidence of Disease" After Complete Surgical Resection of "Locally Advanced" and/or Stage IV Melanoma
NCT01989572 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With "No Evidence of Disease" After Complete Surgical Resection of "Locally Advanced" and/or Stage IV Melanoma
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 23, 2000
- Completion date
- January 31, 2013
- Enrollment
- 815 (actual)
- Sites
- 148
Conditions
As the registry lists them; a condition with its own page is linked.
iris melanoma, medium/large size posterior uveal melanoma, mucosal melanoma, ocular melanoma with extraocular extension, recurrent melanoma, recurrent uveal melanoma, small size posterior uveal melanoma, stage iia cutaneous melanoma ajcc v6 and v7, stage iia uveal melanoma ajcc v7, stage iib cutaneous melanoma ajcc v6 and v7, stage iib uveal melanoma ajcc v7, stage iic cutaneous melanoma ajcc v6 and v7, stage iiia cutaneous melanoma ajcc v7, stage iiia uveal melanoma ajcc v7, stage iiib cutaneous melanoma ajcc v7, stage iiib uveal melanoma ajcc v7, stage iiic cutaneous melanoma ajcc v7, stage iiic uveal melanoma ajcc v7, stage iv cutaneous melanoma ajcc v6 and v7, stage iv uveal melanoma ajcc v7